Avid Bioservices Inc (CDMO)

[pphmtoolong]

Interim results, not this year.

You may be right. You may be wrong. Neither you nor anyone else here knows, because we don't have detailed enrollment information.

If you want credibility, you won't get it this way.

Personally, I expect first and possibly second look-ins this year with stellar results. But without detailed enrollment numbers, there is no way to be sure.

Meanwhile, Peregrine may be sitting in an immuuno-oncology sweet spot. The Bavi-Yervoy trial, which management suggests will have data this year, is testing this hypothesis. Strong results form this small trial data could get a virtuous cycle going.

We'll see this year.

GLTA, Paul